Where the injection went in
About 17 in 100 people had an injection-site reaction, compared with 6 in 100 on a dummy shot.
Read before comparing offers
The label’s cautions, in plain words
Use this page to prepare questions for the prescriber. It cannot say how likely a problem is for you; only a prescriber with your full health picture can.
Compare
Problems seen in the main trials
The current label was checked in September 2026.
Joint pain
About 13 in 100 people reported joint pain, compared with 11 in 100 on a dummy shot.
Blood sugar
About 5 in 100 people reached a diabetes-range blood sugar result, compared with 1 in 100 on a dummy shot.
Fluid retention
The label links held fluid with swelling, joint pain, and carpal tunnel symptoms (numbness or tingling in the hand).
Checklist
Reasons for a deeper review
These are label cautions, not a way to diagnose yourself.
Cancer history
The label rules out active cancer and calls for careful weighing after a past cancer.
Pregnancy
The label rules out use during pregnancy because of possible harm to an unborn baby.
Pituitary damage
The label rules it out when the pituitary gland, which makes growth hormone, has been removed or damaged, for example by surgery, radiation, or a head injury.
IGF-1
IGF-1 is a substance in the blood that rises with growth hormone. In the trials it often went well above normal, and the label calls for blood tests because the long-term effect of that is unknown.
Diabetes
Blood sugar and possible worsening of eye damage need attention.
A fast, severe allergic reaction is an emergency. Call 911.